Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalent to sell US commercial packaging operations
The transaction, which is expected to close in few months, is subject to certain closing conditions and does not involve Catalent’s Clinical Supply Services operations in Philadelphia, or
The transaction, which is expected to close in few months, is subject to certain closing conditions and does not involve Catalent’s Clinical Supply Services operations in Philadelphia, or
The trial met its specified endpoints and FDA’s criteria, in all parameters for bioequivalence, between RedHill’s RHB-103 oral thin-film, and Merck’s Maxalt-MLT. RedHill RHB-103 Product Manager Elkan Gamzu
The patent is issued for the AspirinWorks Test Kit, which measures thromboxane metabolites in urine to evaluate aspirin effect in apparently healthy individuals. The composition-of-matter claims provide intellectual
The targeted peptide inhibits the non-voltage gated calcium channel found in epithelial cancers such as ovarian, breast, prostate and others. SOR-C13 has shown to induce apoptosis, inhibit cell
Patients with chemotherapy, radiotherapy or both, and whose cancer has progressed to treatment and has been confirmed by CT or radiologic scan, were randomized to the trial. Advaxis
UNODC executive director Yury Fedotov said Afghanistan, which produces 90% of the world’s opium, has only seen modest success in the eradication of poppy fields. Afghanisthan president Hamid
The collaborative forum is intended to facilitate the translation of scientific research findings into clinical trials and, eventually, clinical practice. Immuno-oncology focuses on the potential of body’s own
The trial evaluating the safety and tolerability of intravenous ME-344 in escalating dose cohorts of 1.2mg/kg, 2.5mg/kg, 5mg/kg, 10mg/kg and 20mg/kg, will enroll 24 patients into five cohorts.
The McGill patent covers the use of cysteamine and related compounds in the possible treatment of malaria in combination with artemisinin. Raptor chief medical officer Patrice Rioux said
Under the terms of the settlement, pending litigation will be dismissed and Mylan is released from the payment of the $18m jury damage award to Sunovion. Mylan Specialty